Taxis Pharmaceuticals Inc.

Taxis Pharmaceuticals Inc. operates as a federal research grant recipient in the biopharmaceutical space, competing for early-stage antibacterial drug development funding through the Small Business Innovation Research (SBIR) program administered by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The company is a for-profit corporate entity headquartered at Monmouth Junction, New Jersey, with a 100% grant-recipient posture — all three recent federal awards are prime grants, with no contract work or subcontractor engagement in the source record.

Taxis specializes in the discovery and lead optimization of narrow-spectrum oral therapeutics targeting antibiotic-resistant bacterial pathogens. Recent work centers on three proprietary chemical series: FtsZ inhibitors (benzamide class) for Clostridioides difficile infection, dihydrofolate reductase (DHFR) inhibitors for multidrug-resistant Neisseria gonorrhoeae, and efflux pump inhibitors (cyclic aryl-indole series) in combination with levofloxacin against multidrug-resistant Pseudomonas aeruginosa. The company drew on clinical-stage experience with TXA709, an FtsZ inhibitor for MRSA and vancomycin-resistant enterococci, to inform its CDI program. Taxis holds NIAID as its sole federal customer across all three awards.

The company's federal activity consists of three SBIR Phase grants awarded over the past three years. The most recent award, $294,729 granted August 12, 2026, funds Phase I evaluation of FtsZ inhibitors for CDI, with completion by July 31, 2028. A $5 million combined obligated value across the portfolio reflects early-stage R&D funding. A May 2025 Phase II award addresses DHFR inhibitor optimization for multidrug-resistant gonorrhoeae (completion April 30, 2028), and a May 2024 Phase II award covers efflux pump inhibitor development for hospital-acquired and ventilator-associated pneumonia (completion April 30, 2027). All three awards carry ultimate completion dates within the next twenty-four months or immediately beyond, exposing the entire current portfolio to recompete cliff risk.

Taxis Pharmaceuticals Inc is a Small Business located in Monmouth Junction, NJ. Taxis Pharmaceuticals Inc delivers consistent and quality services to its customers with the highest level of integrity and great attention to people, products, and service. They are passionate about their business and go to extraordinary lengths to satisfy their customers. Taxis Pharmaceuticals Inc's vision is to create and strengthen relationships with their customers by providing exceptional service and consistently demonstrating their quality services. Taxis Pharmaceuticals Inc and its employees take great pride in their work and in delighting their customers.